This activity has been designed to meet the educational needs of hematologists, physicians, physician assistants, nurse practitioners, registered nurses, physical therapists, social workers, and other specialists of the hemophilia treatment center (HTC) team, as well as clinicians interested in the treatment and management of patients with hemophilia.
Statement of Need\Program Overview
Hemophilia treatment center clinicians need to remain well-versed in the latest clinical studies and trials to provide their patients with optimal care. However, not all members of hemophilia treatment teams have the opportunity to attend medical congresses, where the most up-to-date information regarding the treatment and management of patients with hemophilia is presented and discussed. This activity, derived from scientific posters and abstracts presented at recently held congresses, enables clinicians to become current on pivotal issues in hemophilia care while learning from key opinion leaders in this disease state.
After completing this activity, the participant should be better able to:
Steven W. Pipe, MD
- Discuss new clinical data from recently presented abstracts and scientific posters about hemophilia
- Implement individual treatment strategies based on both evidence and hemophilia expert opinion and recommendations
- Discuss the burden of illness in hemophilia patients, including school/work absenteeism, employment status,
and physical pain, and its impact on quality of life
- Formulate a diagnostic plan and laboratory workup for a person suspected of having acquired hemophilia A
- Compare clinical data on the perioperative use of bypassing agents in hemophilia patients with inhibitors
- Describe the current surgical practices of US-based hemophilia treatment centers
- Provide appropriate care and counsel for patients and their families
Department of Pediatrics and Pathology
C. S. Mott Children's Hospital
University of Michigan
Ann Arbor, Michigan
Michael Recht, MD, PhD
Associate Professor of Pediatrics and Medicine
Director, The Hemophilia Center
Oregon Health & Science University
Brenda Riske, RN, MS, MBA, MPA
Director of Operations, Clinical Services & Research
University of Colorado School of Medicine
Center for Bleeding and Clotting Disorders
Donald L. Yee, MD
Assistant Professor of Pediatrics
Baylor College of Medicine
Director, Texas Children's Hemophilia & Thrombosis Center
Mark T. Reding, MD
Associate Professor of Medicine
Division of Hematology, Oncology, and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Leonard Valentino, MD
Hemophilia and Thrombophilia Center
Rush University Medical Center
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine, the Cardiovascular & Metabolic Health Foundation, and Educational Concepts in Medicine. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
This educational activity for 0.8 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Method of Participation
During the period December 6, 2011 through December 6, 2012, participants must:
- Read the learning objectives and faculty disclosures
- Study the educational activity
- Complete the posttest by recording the best answer to each question
- Complete the evaluation form
A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The planning committee and presenting faculty
reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter
Reported Financial Relationship
|Steven W. Pipe, MD
|Consulting Fees: Baxter BioScience, Novo Nordisk Inc., Pfizer Inc.; Fees for Non-CME/CE Services Received Directly From a Commercial Interest or Their Agents: CSL Behring; Contracted Research: Inspiration Biopharmaceuticals
|Michael Recht, MD, PhD
|Contracted Research: Baxter Healthcare Corporation, Novo Nordisk Inc., Pfizer Inc.
|Mark T. Reding, MD
|Consulting Fees: Bayer HealthCare, Biogen Idec, Novo Nordisk Inc., Pfizer Inc.
|Brenda Riske, RN, MS, MBA, MPA
|Consulting Fees: Bayer HealthCare
|Leonard Valentino, MD
|Has no real or apparent conflicts of interest to report.
|Donald L. Yee, MD
|Consulting Fees: Baxter Healthcare Corporation; Contracted Research: Novo Nordisk Inc.
The planners and managers
reported the following financial relationships or relationships to products or
devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager
Reported Financial Relationship
|PIM Clinical Reviewers: Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN
|Have no real or apparent conflicts of interest to report.
|ECM: Pat Crowley, MBA, Managing Director; Jodi Andrews, BS, Associate Director, Educational Programs; Cassie Gangeri, BA, Senior Program Manager; Gay Boyle, MA, Manager, Editorial Services
||Have no real or apparent conflicts of interest to report.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Cardiovascular & Metabolic Health Foundation (CMH), Educational Concepts in Medicine (ECM), and Novo Nordisk Inc. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, CMH, ECM, and Novo Nordisk Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an educational grant from Novo Nordisk Inc.